Zevra Therapeutics, Inc. Payments of Financing Costs
Zevra Therapeutics, Inc. (ZVRA) reported Payments of Financing Costs of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2026-03-09
- Zevra Therapeutics, Inc. payments of financing costs for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- Zevra Therapeutics, Inc. payments of financing costs for the quarter ending 2017-09-30 was $0.00.
- Zevra Therapeutics, Inc. payments of financing costs for the quarter ending 2017-06-30 was $24.00K.
- Zevra Therapeutics, Inc. payments of financing costs for the quarter ending 2017-03-31 was $26.00K.
- Zevra Therapeutics, Inc. payments of financing costs for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Zevra Therapeutics, Inc. payments of financing costs for fiscal 2024 was $2.09M.
- Zevra Therapeutics, Inc. payments of financing costs for fiscal 2023 was $0.00.
- Zevra Therapeutics, Inc. payments of financing costs for fiscal 2018 was $184.00K, a 268.00% increase from fiscal 2017.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-09 | |||
| 2024-12-31 | $2.09M 10-K · filed 2026-03-09 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-12 | |||
| 2018-12-31 | $184.00K 10-K · filed 2019-03-01 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $0.00 derived: sum of 2 quarters · filed 2019-03-01 | $24.00K derived: sum of 3 quarters · filed 2019-03-01 | $50.00K 10-K · filed 2019-03-01 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $24.00K derived: sum of 2 quarters · filed 2018-11-09 | $50.00K 10-Q · filed 2018-11-09 | $174.00K derived: sum of 4 quarters · filed 2018-11-09 |
| 2017-06-30 | $24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | $50.00K 10-Q · filed 2018-08-10 | $174.00K derived: sum of 3 quarters · filed 2018-08-10 | |
| 2017-03-31 | $26.00K 10-Q · filed 2018-05-11 | $150.00K derived: sum of 2 quarters · filed 2018-05-11 | ||
| 2016-12-31 | $124.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30 | $164.00K 10-K · filed 2018-03-30 | ||
| 2016-09-30 | $40.00K 10-Q · filed 2017-11-09 | |||
| 2015-12-31 | -$929.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30 | -$353.00K derived: sum of 2 quarters · filed 2018-03-30 | $315.00K 10-K · filed 2018-03-30 | |
| 2015-09-30 | $576.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $1.24M 10-Q · filed 2016-11-10 | ||
| 2015-06-30 | $668.00K 10-Q · filed 2016-08-11 | |||
| 2014-12-31 | $1.77M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |